Effect of Cyperus rotundus on cytokine gene expression in experimental inflammatory bowel disease

Iranian Journal of Medical Sciences

Volumn 41, Issue 5, 2016, Pages 391-398

  Johari, Sarika ^a   Joshi, Chaitanya ^b   Gandhi, Tejal ^a  

^a ANAND PHARMACY COLLEGE   (India)

^b Chhattisgarh Kamdhenu Vishwa Vidyalaya   (India)

Author keywords

Cyperus rotundus; Inflammatory bowel diseases; Interleukin 12; Interleukin 18; Interleukin 4; Interleukin 6

Indexed keywords

ALCOHOL; CYPERUS ROTUNDUS EXTRACT; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; MESALAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CYPERUS ROTUNDUS; CYTOKINE GENE; DRUG EFFECT; DRUG EFFICACY; DRUG ISOLATION; EXPERIMENTAL INFLAMMATORY BOWEL DISEASE; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; IFN GEMMA GENE; IL 12 GENE; IL 4 GENE; IL 6 GENE; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; MALE; NONHUMAN; OUTCOME ASSESSMENT; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; RAT; TREATMENT RESPONSE; UPREGULATION;

EID: 84984781197     PISSN: 02530716     EISSN: 17353688     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066-78. doi: 10.1056/NEJMra0804647. PubMed PMID: 19923578; PubMed Central PMCID: PMC3491806.
2. Neuman MG. Signaling for inflammation and repair in inflammatory bowel disease. Rom J Gastroenterol. 2004;13:309-16. PubMed PMID: 15624029.
3. Triantafillidis JK. The use of natural products in the treatment of inflammatory bowel disease. Ann Gastroenterol. 2008;21:14-6.
4. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-57. doi: 10.1016/S0140-6736(07)60751-X. PubMed PMID: 17499606.
5. D’Inca R, Garribba AT, Vettorato MG, Martin A, Martines D, Di Leo V, et al. Use of alternative and complementary therapies by inflammatory bowel disease patients in an Italian tertiary referral centre. Dig Liver Dis. 2007;39:524-9. doi: 10.1016/j.dld.2007.03.001. PubMed PMID: 17433794.
6. Clarke JO, Mullin GE. A review of complementary and alternative approaches to immunomodulation. Nutr Clin Pract. 2008;23:49-62. doi: 10.1177/011542650802300149. PubMed PMID: 18203964.
7. Sharma PC, Yelne MB, Dennis TJ, Joshi A. Database on medicinal plants used in Ayurveda. Volume 3. New Delhi: Pearl Offset Press Pvt. Ltd.; 2005.
8. Pal D, Dutta S, Sarkar A. Evaluation of CNS activities of ethanol extract of roots and rhizomes of Cyperus rotundus in mice. Acta Pol Pharm. 2009;66:535-41. PubMed PMID: 19894649.
9. Mayur P, Pawan P, Ashwin S, Pravesh S. Evaluation of anticonvulsant activity of roots and rhizomes of Cyperus rotundus Linn. in mice. International Research Journal of Pharmacy. 2011;2:37-41.
10. Yuan H, Ji WS, Wu KX, Jiao JX, Sun LH, Feng YT. Anti-inflammatory effect of Diammonium Glycyrrhizinate in a rat model of ulcerative colitis. World J Gastroenterol. 2006;12:4578-81. doi: 10.3748/wjg.v12.i28.4578. PubMed PMID: 16874877; PubMed Central PMCID: PMC4125652.
11. Seo EJ, Lee DU, Kwak JH, Lee SM, Kim YS, Jung YS. Antiplatelet effects of Cyperus rotundus and its component (+)-nootkatone. J Ethnopharmacol. 2011;135:48-54. doi: 10.1016/j.jep.2011.02.025. PubMed PMID: 21354294.
12. Chandratre R, Chandarana S, Mengi S. Lipid lowering activity of alcoholic extract of Cyperus rotundus. Int J Res Pharm Chem. 2011;1:1042-45.
13. Shamkuwar PB, Hoshamani AH, Gonjari I. Antispasmodic effect of Cyperus Rotundus L.(Cyperaceae) in diarrhoea. Pharm Lett. 2012;4:522-4.
14. Sarika J, Tejal G. Protective Effect of Chloroform Extract of Cyperus Rotundus against DNBS Induced Inflammatory Bowel Disease in Rats. Research & Reviews: A Journal of Pharmacology. 2015;4:24-32.
15. Khandelwal KR. Practical Pharmacognosy techniques and experiments. 16th ed. Pune: Nirali Prakashan; 2006. p. 149-61.
16. Kokate CK. Practical Pharmacognosy. 4th ed. New Delhi: Vallabh Prakashan; 2009. p. 107-11.
17. OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects. Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents. 2001. Available from: http://www.oecd.org/env/test-no-407-repeated-dose-28-day-oral-toxicity-study-inrodents-9789264070684-en.htm
18. Cuzzocrea S, Mazzon E, Di Paola R, Patel NS, Genovese T, Muia C, et al. Erythropoietin reduces the development of experimental inflammatory bowel disease. J Pharmacol Exp Ther. 2004;311:1272-80. doi: 10.1124/jpet.104.073197. PubMed PMID: 15302898.
19. Wu Z, Turner DR, Oliveira DB. IL-4 gene expression up-regulated by mercury in rat mast cells: a role of oxidant stress in IL-4 transcription. Int Immunol. 2001;13:297-304. doi: 10.1093/intimm/13.3.297. PubMed PMID: 11222498.
20. Pizarro TT, De La Rue SA, Cominelli F. Role of interleukin 6 in a murine model of Crohn’s ileitis: are cytokine/anticytokine strategies the future for IBD therapies? Gut. 2006;55:1226-7. doi: 10.1136/gut.2005.083121. PubMed PMID: 16905692; PubMed Central PMCID: PMC1860037.
21. Carey R, Jurickova I, Ballard E, Bonkowski E, Han X, Xu H, et al. Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:446-57. doi: 10.1002/ibd.20342. PubMed PMID: 18069684; PubMed Central PMCID: PMC2581837.
22. Sagiv-Friedgut K, Karban A, Weiss B, Shaoul R, Shamir R, Bujanover Y, et al. Early-onset Crohn disease is associated with male sex and a polymorphism in the IL-6 promoter. J Pediatr Gastroenterol Nutr. 2010;50:22-6. doi: 10.1097/MPG.0b013e3181b7a6a4. PubMed PMID: 19934771.
23. Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, Zeuzem S, et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn’s disease but not in ulcerative colitis. Inflammatory bowel diseases. 2005;11:16-23.
24. Nielsen OH, Kirman I, Rudiger N, Hendel J, Vainer B. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand J Gastroenterol. 2003;38:180-5. doi: 10.1080/00365520310000672. PubMed PMID: 12678335.
25. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79-94. doi: 10.1128/CMR.15.1.79-94.2002. PubMed PMID: 11781268; PubMed Central PMCID: PMC118061.
26. Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn’s disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol. 2006;12:5606-10. doi: 10.3748/wjg.v12.i35.5606. PubMed PMID: 17007011; PubMed Central PMCID: PMC4088159.
27. Lin F-C, Young HA. The talented interferongamma. Adv Biosci Biotechnol. 2013;4:6. doi: 10.4236/abb.2013.47A3002.
28. Ito R, Shin-Ya M, Kishida T, Urano A, Takada R, Sakagami J, et al. Interferongamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol. 2006;146:330-8. doi: 10.1111/j.1365-2249.2006.03214.x. PubMed PMID: 17034586; PubMed Central PMCID: PMC1942055.